Wolfgang Miesbach: CMA CAR-T Induces Immune Reset and Durable Remission in Refractory ITP – EHA 2026 Late-Breaking Update
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Jinhui Shu et al, adding։
“Looking ahead to EHA 2026 next week, I am particularly interested in an upcoming late-breaking presentation:
- BCMA CAR-T Cell Therapy Induces Comprehensive Immune Resetting and Durable Remission in Refractory Primary Immune Thrombocytopenia
Targeting plasma cells and pathogenic antibody production represents a promising mechanistic shift beyond traditional B-cell–directed approaches.
It will be exciting to see how these strategies translate into clinical responses and immune modulation.”
Title: BCMA CAR-T cell therapy induces comprehensive immune resetting and durable remission in refractory primary immune thrombocytopenia
Authors: Jinhui Shu, Min Xu, Wei Xie, Lin Liu, Peiru Li, Hongjian Li, James Bussel, Yu Hu, Heng Mei
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI